Role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Peritoneal Carcinomatosis of Appendiceal and Colorectal Origin
DOI:
https://doi.org/10.5281/zenodo.23323160Keywords:
Peritoneal carcinomatosis, Cytoreductive surgery, Hyperthermic intraperitoneal chemotherapy, Colorectal neoplasms, Appendiceal neoplasmsAbstract
Peritoneal carcinomatosis of appendiceal and colorectal origin represents a therapeutic challenge due to the high frequency of recurrence and the limitations of systemic treatment alone. This review aimed to analyze the role of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of these malignancies, considering clinical outcomes, survival, and prognostic factors. Fifty-seven studies were identified, of which nine were selected for analysis. The findings indicated that CRS combined with HIPEC may provide disease control and survival benefits in carefully selected patients. Complete cytoreduction emerged as one of the main factors associated with better outcomes, while the extent of peritoneal disease, primary tumor origin, lymph node involvement, and postoperative complications also influenced prognosis. Evidence regarding additional systemic chemotherapy was heterogeneous, particularly in appendiceal tumors, highlighting the need for individualized treatment strategies. In conclusion, CRS and HIPEC represent a relevant therapeutic approach for selected patients, provided that treatment is preceded by multidisciplinary assessment and performed at experienced centers.
References
1. Kuncewitch M, Levine EA, Shen P, Votanopoulos KI. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal tumors and colorectal adenocarcinomas. Clin Colon Rectal Surg. 2018;31(5):288-294. doi:10.1055/s-0038-1642052.
2. Harper MM, Kim J, Pandalai PK. Current trends in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal disease from appendiceal and colorectal malignancies. J Clin Med. 2022;11(10):2840. doi:10.3390/jcm11102840.
3. Shah R, Gangi A. Role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of colorectal peritoneal metastases. Clin Colon Rectal Surg. 2024;37(2):90-95. doi:10.1055/s-0042-1758759.
4. Quénet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256-266. doi:10.1016/S1470-2045(20)30599-4.
5. Cashin P, Sugarbaker PH. Hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases: lessons learned from PRODIGE 7. J Gastrointest Oncol. 2021;12(Suppl 1):S120-S128. doi:10.21037/jgo-2020-05.
6. Kuncewitch M, Levine EA, Shen P, Votanopoulos KI. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal tumors and colorectal adenocarcinomas. Clin Colon Rectal Surg. 2018;31(5):288-294. doi:10.1055/s-0038-1642052.
7. Shah R, Gangi A. Role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of colorectal peritoneal metastases. Clin Colon Rectal Surg. 2024;37(2):90-95. doi:10.1055/s-0042-1758759.
8. Gao Y, Wang X. Current status and progress of diagnosis and treatment of postoperative recurrence of gastrointestinal peritoneal metastases. Holist Integr Oncol. 2025;4:27.
9. Harper MM, Kim J, Pandalai PK. Current trends in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal disease from appendiceal and colorectal malignancies. J Clin Med. 2022;11(10):2840. doi:10.3390/jcm11102840.
10. Brar G, Castillo D, Lwin T, et al. The role of systemic chemotherapy to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with appendiceal cancers. Clin Colorectal Cancer. 2026;25:209-215.
11. Dinçer B, Gök AFK, İlhan M, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy outcomes in peritoneal carcinomatosis: 11-year tertiary-center experience. BMC Cancer. 2025;25:479. doi:10.1186/s12885-025-13858-x.
12. Reese M, Eichelmann AK, Nowacki TM, et al. The role of cytoreductive surgery and HIPEC for the treatment of primary and secondary peritoneal malignancies: experience from a tertiary care center in Germany. Langenbecks Arch Surg. 2024;409:113. doi:10.1007/s00423-024-03309-9.
13. Morris M, Cloyd J, Hays J, et al. The role of hyperthermic intraperitoneal chemotherapy for noncolorectal peritoneal surface malignancies. J Gastrointest Surg. 2021;25:303-318.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Ana Hisi Fujii Ramos, Gabriela Hitomi Ohara, Vitor Santos Facin, Samira Fonseca Nogueira Petermann Kyono, Natalia de Souza Ferreira, Maitê Carrato Alexandre
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os artigos publicados na International Journal of Health and Surgical Research são licenciados sob a Creative Commons Attribution 4.0 International (CC BY 4.0).
Isso permite que outros distribuam, remixem, adaptem e criem a partir do trabalho publicado, para qualquer finalidade, incluindo comercial, desde que seja dado o devido crédito ao autor original e à revista.
Os autores mantêm os direitos autorais de seus trabalhos e concedem à revista o direito de primeira publicação.
